A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease

This is a Phase 2b study investigating the efficacy and safety of mesdopetam as adjunct therapy on daily ON-time without troublesome dyskinesia in patients with Parkinson disease. Mesdopetam is taken for 84 days.

开始日期2020-10-29

申办/合作机构

IRLAB Therapeutics AB

NCT03368170

/ Completed临床2期

A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a side-effect frequently occurring with long-term levodopa treatment in patients with Parkinson's disease. In experimental animals mesdopetam potently reduced levodopa-induced involuntary movement without impairing the antiparkinsonian effect of levodopa.
The primary purpose of the trial is to investigate whether mesdopetam given as adjunctive treatment can reduce levodopa induced dyskinesia in patients with Parkinson's disease. The trial will also help to establish the most optimal dosing of the compound.

开始日期2018-04-12

申办/合作机构

IRLAB Therapeutics AB

[+1]

NCT03531060

/ Completed临床1/2期

A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).

This is a Phase 1b study investigating the safety and tolerability of IRl790 as adjunct therapy in patients with Parkinson disease. IRL790/placebo is taken for 28 days.

开始日期2016-11-08

申办/合作机构

IRLAB Therapeutics AB

100 项与 Mesdopetam 相关的临床结果

登录后查看更多信息

100 项与 Mesdopetam 相关的转化医学

登录后查看更多信息

100 项与 Mesdopetam 相关的专利（医药）

登录后查看更多信息

项与 Mesdopetam 相关的文献（医药）

2026-04-01·CURRENT OPINION IN NEUROBIOLOGY

The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease

Review

作者: Huot, Philippe ; Teil, Margaux

An important part of the field of experimental pharmacology encompasses the study of the effects of molecules in animals. In the case of Parkinson's disease (PD), animal models have played an invaluable role in refining our understanding of the disease, in characterizing the effect of new compounds on the illness, and in bringing new treatments to the clinic. Indeed, it is now hardly conceivable that a drug would be tested in humans if several parameters pertaining to safety, toxicology, efficacy, etc. had not previously been evaluated in animal models. Quite unfortunately, efficacy in experimental models of PD does not necessarily guarantee positive clinical outcomes. In this article, which primarily focusses on the past five years, we review drugs that entered clinical trials for the treatment of levodopa-induced dyskinesia, parkinsonism, disease modification, and had previously been assessed in animal models of PD. The drugs discussed are buspirone, JM-010, befiradol, mesdopetam, foliglurax, dipraglurant, tavapadon, prasinezumab, cinpanemab, nilotinib, minzasolmin, exenatide, NLY01, liraglutide, lixisenatide, and semaglutide. For each molecule, we examine how previous preclinical studies succeeded or failed in predicting efficacy in clinical trials and discuss possible ways to optimize animal-model design and selection to maximize the probability of translational success.

2025-06-01·Movement Disorders Clinical Practice

Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial

Article

作者: Angelo Antonini MD, PhD ; Joakim Tedroff MD, PhD ; Susanna Waters MD, PhD ; Fabricio Stocchi MD, PhD ; Padraig O'Suilleabhain MD ; Johanna Landström MSc ; Clas Sonesson PhD

Abstract:

Background:

The treatment of levodopa‐induced dyskinesia in Parkinson's disease (PD) is a largely unmet need.

Objectives:

Mesdopetam is a novel small molecule dopamine D3 receptor antagonist aimed for the treatment of levodopa‐induced dyskinesia. This was a phase 2b study dose finding study to investigate efficacy and safety of 2.5 mg, 5 mg and 7,5 mg b.i.d. in a randomized controlled trial.

Methods:

PD patients with ≥2 hours of troublesome dyskinesia were randomized to placebo or mesdopetam twice daily for 12 weeks. The primary efficacy endpoint was change from baseline to week 12 in ON time without troublesome dyskinesia (Good ON‐time) as recorded with home diaries. Secondary efficacy endpoints assessing ON phase dyskinesia were the modified UDysRS (sum of parts 1, 3 and 4) and MDS‐UPDRS part 4.2.

Results:

Groups did not differ in change from baseline to end of study in Good ON‐time. Several secondary assessments for ON phase dyskinesia such as the modified UDysRS showed clinically relevant and statistically significant improvements for the 2.5 and 7.5 mg doses. OFF time showed dose dependent decrease with highest efficacy for the 7.5 mg dose. The adverse event profile was similar to placebo.

Conclusions:

In this study mesdopetam failed to increase Good ON‐time as compared to placebo. However, a statistically significant and clinically meaningful improvement in the prespecified secondary efficacy endpoint UDysRS warrants further investigation. Results from this dose finding study suggest 7.5 mg b.i.d. to be the preferred dose for further study.

2025-03-01·EUROPEAN JOURNAL OF NEUROSCIENCE

Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia

Article

作者: Petersson, Per ; Ronaghi, Abdolaziz ; Malinina, Evgenya ; Barrientos, Sebastian A. ; Sato, Sebastian Sulis ; Tedroff, Joakim ; Nasretdinov, Azat ; Censoni, Luciano ; Stan, Tiberiu Loredan ; Halje, Pär ; Waters, Nicholas

ABSTRACT:

Levodopa provides effective symptomatic treatment for Parkinson's disease. However, nonmotor symptoms are often insufficiently relieved, and its long‐term use is complicated by motor fluctuations and dyskinesia. To clarify mechanisms of levodopa‐induced dyskinesia and pharmacological interventions aimed at reducing dyskinetic symptoms, we have here characterized the neurophysiological activity patterns in sensorimotor and cognitive‐limbic circuits in dyskinetic rats, comparing the effects of amantadine, pimavanserin, and the novel prospective antidyskinetic and antipsychotic treatment mesdopetam. Parallel recordings of local field potentials from 11 cortical and subcortical regions revealed suppression of narrowband gamma oscillations (NBGs) in sensorimotor structures by amantadine and mesdopetam in conjunction with alleviation of dyskinetic signs. Concomitant gamma oscillations in cognitive‐limbic circuits were not directly linked to dyskinesia and were not affected by antidyskinetic treatments to the same extent, although treatment‐induced reductions in functional coupling were observed in both sensorimotor and cognitive‐limbic circuits, in parallel. In a broad frequency spectrum (1–200 Hz), mesdopetam treatment displayed greater similarities to pimavanserin than to amantadine. These findings point to the reduction of NBGs as a valuable biomarker for the characterization of antidyskinetic treatment effects and provide systems‐level mechanistic insights into the antidyskinetic efficacy of mesdopetam, with potential additional benefits for the treatment of Parkinson's‐related psychosis.

108

项与 Mesdopetam 相关的新闻（医药）

2026-01-19

·BioSpace

IRLAB Enters Collaboration Agreement with Danish Biotech Company Biomia ApS Applying the Integrative Screening Process (ISP)

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, SE / ACCESS Newswire / January 19, 2026 / IRLAB Therapeutics AB (STO:IRLAB-A)(FRA:6IRA), a company discovering and developing novel treatments for Parkinson's disease, today announced that it has entered into a collaboration with the Danish biotech company Biomia to evaluate Biomia's drug candidates applying IRLAB's discovery platform, the Integrative Screening Process (ISP). "We are excited to enter into an ISP-based collaboration with Biomia, giving us the opportunity to leverage our broad expertise in drug discovery for CNS disorders. The ISP platform has proven its ability for discovery of entirely novel drug candidates with blockbuster potential across CNS disorders. Biomia's unique strategy for lead identification and innovative synthesis of compounds makes a good match with our discovery platfom," says Kristina Torfgård, CEO. In the collaboration, IRLAB will use its ML/AI-supported technology platform, the Integrative Screening Process (ISP) for phenotypic characterization and evaluation of small-molecule compounds, to provide in depth characterization of Biomia's novel chemistries and compounds. ISP will be ulilized to characterize the novel compounds as well as predict potential target indications and includes differentiation vs. currently available treatments for several undisclosed CNS indications. Biomia supplies the project with its compounds and finances the studies that IRLAB accomplish. For more information Kristina Torfgård, CEO Phone: +46 730 60 70 99 E-mail: kristina.torfgard@irlab.se About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments IRLAB enters collaboration agreement with Danish biotech company Biomia ApS applying the Integrative Screening Process (ISP) SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

临床2期临床1期

2025-12-23

·BioSpace

IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GOTHENBURG, NE / ACCESS Newswire / December 23, 2025 / IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A)(STO:IRLAB-A)(FRA:6IRA), a company focused on discovering and developing new treatments for Parkinson's disease, has received regulatory and ethical approvals for a Phase Ib study of IRL757 to assess safety, tolerability, and signal finding in patients with Parkinson's disease who experience apathy. The study will be conducted at 16 sites across four European countries and is fully funded by IRLAB's development collaborator, the McQuade Center for Strategic Research and Development, LLC (MSRD) -an indirect subsidiary of Otsuka Pharmaceutical Co., Ltd. "We are excited about the Phase Ib Signal Finding Study of our drug candidate, IRL757, in Parkinson's patients experiencing apathy. This condition causes significant disability for many individuals living with Parkinson's disease. Currently, there is a substantial medical need for an effective treatment of apathy which lacks treatment options. With strong scientific and financial backing from our collaborator MSRD, we have developed this first-in-class drug candidate very efficiently," says Kristina Torfgård, CEO of IRLAB. The study, which will include 75 patients with Parkinson's disease who experience apathy, will be conducted at study sites in Germany, Bulgaria, Poland, and Spain. Two previous Phase I studies, one in healthy young adults and one in healthy older adults aged 65 and above, both showed that IRL757 was well absorbed and provided good systemic exposure after 10 days of dosing. All participants completed both studies, and no serious adverse events were recorded. Apathy is characterized by indifference, resignation, and a lack of response to what is happening in the outside world. The condition often leads to significant disability affecting a substantial proportion of people living with Parkinson's disease, and with other neurodegenerative diseases. Currently, there are no drugs on the market to treat apathy. IRLAB and MSRD, a member of the global Otsuka group of companies, formed a collaboration in May 2024 to advance IRL757 through proof-of-concept trials as a potential treatment for apathy. IRLAB's drug candidate IRL757 has shown positive effects in several preclinical models of cognitive function, including improved motivation. This effect is believed to be associated with the drug candidate's ability to counteract disturbances in central nervous system nerve signalling proposed to underly apathy in several neurological conditions. For more information Kristina Torfgård, CEO Phone: +46 730 60 70 99 E-mail: kristina.torfgard@irlab.se Nicholas Waters, EVP and Head of R&D Phone: +46 730 75 77 01 E-mail: nicholas.waters@irlab.se About IRL757 The drug candidate IRL757 is being developed as a treatment for apathy in Parkinson's disease and other neurological conditions. Apathy, a widespread and debilitating issue, affects over 20 million people in the U.S. and Europe alone without a currently available treatment. The prevalence is high, occurring in 1.1-4 million people (20-70 percent) being treated with Parkinson's in the eight major markets (China, EU5, Japan, and the US), and in 4.9-6.7 million people (43-59 percent) being treated for Alzheimer's disease in the ten major markets (Canada, China, EU5, Japan, South Korea, and the US). IRL757 has the potential to become the first treatment for apathy. The efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signalling, a key factor believed to contribute to apathy in neurological disorders. About IRLAB IRLAB discovers and develops a portfolio of transformative treatments for all stages of Parkinson's disease. The company originates from Nobel Laureate Prof Arvid Carlsson's research group and the discovery of a link between brain neurotransmitter disorders and brain diseases. Mesdopetam (IRL790), under development for treating levodopa-induced dyskinesias, has completed Phase IIb and is in preparation for Phase III. Pirepemat (IRL752), currently in Phase IIb, is being evaluated for its effect on fall frequency in Parkinson's disease. IRL757, a compound being developed for the treatment of apathy in neurodegenerative disorders, is in Phase I. In addition, the company is developing two preclinical programs, IRL942 and IRL1117, towards Phase I studies. IRLAB's pipeline has been generated by the company's proprietary systems biology-based research platform Integrative Screening Process (ISP). Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit . Attachments IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease SOURCE: IRLAB Therapeutics View the original press release on ACCESS Newswire

临床1期临床2期

2025-11-18

·钟书神经药研所

IRLAB宣布两篇研究摘要将在2026年AD/PD大会发表，专注帕金森病创新药物研发

点击上方蓝字关注“钟书神经药研所” 当地时间2025年11月7日，一家专注于帕金森病新疗法研发的公司IRLAB Therapeutics宣布，有两篇研究摘要将于2026年3月17-21日在哥本哈根举行的国际阿尔茨海默病/帕金森病（AD/PD）大会进行展示。 IRLAB公司致力于针对各阶段的帕金森病研发创新疗法，公司源自诺贝尔奖得主Arvid Carlsson教授研究团队，其重大发现揭示了脑神经递质紊乱与脑疾病之间的关联。 "我们非常期待参与这场全球帕金森病研究领域的顶级科学盛会。" IRLAB首席执行官Kristina Torfgård表示，"这为我们提供了积极贡献研究成果、拓展专业网络并增强研发管线信心的宝贵机会。" 公司入选2026年AD/PD的两篇摘要标题如下：《REACT-PD研究结果：一项评估pirepemat对帕金森患者跌倒频率疗效的随机、安慰剂对照、多中心IIb期研究》《运用整合筛选流程（ISP）探索帕金森与阿尔茨海默病新型CNS疗法：基于人工智能/机器学习的表型药物发现平台》根据官网公开信息，IRLAB目前处于临床后期的研发管线包括两款产品：用于治疗左旋多巴诱导异动症的的mesdopetam（IRL790），已完成IIb期研究，正在筹备III期临床研究；针对跌倒频率改善的pirepemat（IRL752），目前处于IIb期研究阶段； Mesdopetam：新型D3受体拮抗剂，临床2b研究未达主要研究终点 Mesdopetam 是一种新型多巴胺 D3 受体拮抗剂，D3受体被认为在左旋多巴诱导异动症（LID）的病理生理学中起关键作用。临床前研究表明，Mesdopetam 具有抗异动症的功效，同时可能具有抗精神病性症状的作用。已完成的随机、双盲、安慰剂对照的IIb期研究评估了三种剂量（2.5 mg, 5 mg, 7.5 mg，每日两次）的Mesdopetam在156名帕金森病伴LID患者中的疗效和安全性，治疗周期为12周。非常遗憾的是，该研究未达到主要研究终点，与安慰剂相比，Mesdopetam治疗组患者“良好开期时间”从基线到第12周的变化未显示出有临床意义的变化。尽管在其他预设的次要终点上，Mesdopetam显示出具有临床意义和统计学显著性的改善，包括：改良统一异动症量表评分（UDysRS）总分： 7.5 mg剂量组相比安慰剂改善了6.2分（p<0.05）。 UDysRS异动症残疾评分：基于实际服用剂量的分析显示，7.5 mg剂量组相比安慰剂改善了3.9分（p=0.045）。关期时间： 7.5 mg剂量组相比安慰剂减少了每日0.7小时关期时间。 Mesdopetam整体安全性和耐受性良好，与安慰剂相似。未发现对生命体征、实验室参数（包括催乳素水平）有影响，不增加幻觉、头晕、跌倒或抗胆碱能样副作用的风险。 Pirepemat：独特机制的“防摔倒”小分子产品 IRLAB公司旗下另一款处于临床2b期的小分子产品是Pirepemat，其作用机制非常独特，它并非直接针对多巴胺系统来改善运动功能，而是专注于改善认知和大脑的额叶功能，从而间接防止跌倒。其核心机制是双重作用：阻断α2A/C-肾上腺素能受体：大脑前额叶皮层富含这些受体，它们的功能与工作记忆、执行功能和注意力等高级认知功能密切相关。通过阻断这些受体，Pirepemat可以增强前额叶皮层的去甲肾上腺素和 dopamine D1 受体信号传导。这被认为能够改善患者的“认知灵活性”和规划能力，使其在行走时能更好地处理环境信息并避免绊倒。弱激动5-HT1A受体：这个作用可能有助于平衡药物的激活效应，减少潜在的焦虑或紧张副作用，使药物的耐受性更好。简单来说，Pirepemat用于PD患者“防摔倒”的核心理念是：许多帕金森病患者的跌倒，并非单纯由于肢体僵硬或平衡差，而是因为与疾病相关的认知障碍，导致他们无法在行走时同时处理多项任务（如避开障碍物、转弯、保持平衡）。 Pirepemat通过“唤醒”负责这些功能的大脑区域（前额叶皮层），来帮助患者更安全地行走，从而减少跌倒。一项纳入104名PD患者的IIb期研究（REACT-PD）已完成，公司在2025年3月报告了主要研究结果。 PD患者接受每日600mg的Pirepemat治疗3个月后，跌倒发生率降低了42%；然而，与安慰剂相比，这一效应未达到统计学显著性。基于对Pirepemat临床IIb期剂量发现和疗效研究中产生的预设且深入的疗效分析，进一步结果显示，在中等血浆浓度范围内，Pirepemat在三个月治疗后，患者跌倒发生率可降低多达51.5%，且具有统计学显著性差异（p<0.05，对比安慰剂）。此外，该公司旗下还有一款用于治疗神经退行性疾病淡漠症状的IRL757，目前正在进行临床I期研究；而IRL942和IRL117两个临床前项目也正在准备推进至I期研究阶段。更多阅读：艾伯维向FDA提交多巴胺D1/D5受体激动剂tavapadon用于治疗帕金森病的新药上市申请拜耳旗下帕金森病基因治疗产品18个月随访数据发表，显著改善运动症状评分和异动症评分 Gain Theraputics 召开KOL会议讨论小分子Gcase酶调节剂治疗帕金森病临床1b期中期数据主要参考资料： 1.https://irlab.se/mfn_news/irlab-receives-acceptance-for-two-abstracts-at-ad-pd-2026-the-20th-international-conference-on-alzheimers-and-parkinsons-diseases/ 2.https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mdc3.70004 3.https://irlab.se/project-portfolio/irl-752/ 4.https://irlab.se/wp-content/uploads/2025/10/IRLAB-Q3-2025-presentation.pdf 声明：本文图片和内容主要来自官方和新闻网站，以及公开发表的学术会议或文献信息，如涉及版权问题，请联系删除。本文内容仅供信息分享和学术探讨之用，不构成任何形式的医学建议或健康指导。文｜神经小迷妹医学科普药学资讯长按关注

临床2期临床结果临床3期临床成功临床失败

100 项与 Mesdopetam 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
药物性运动障碍	临床2期	美国	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	法国	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	以色列	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	意大利	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	波兰	IRLAB Therapeutics AB	2020-10-29
药物性运动障碍	临床2期	塞尔维亚	IRLAB Therapeutics AB	2020-10-29
帕金森病	临床2期	瑞典	IRLAB Therapeutics AB	2018-04-12
帕金森病	临床2期	英国	IRLAB Therapeutics AB	2018-04-12
运动失调	临床2期	-	IRLAB Therapeutics AB	2016-11-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04435431 (CTgov)	临床2期	药物性运动障碍 \| 帕金森病	155	Placebo	餘夢淵鑰壓簾鹹製遞觸(壓蓋壓築壓網選餘鹽壓) = 觸壓範築範簾構艱壓製遞簾醖繭廠糧網繭憲選 (廠糧艱醖糧製鏇繭糧築, 0.4776) 更多	-	2024-03-06
NCT04435431 \| EUCTR2020-002010-41-FR (Biospace) 人工标引	临床2期	帕金森病	156	mesdopetam	齋鑰製夢製簾膚鏇窪衊(餘選醖遞鹽憲鏇壓憲鑰) = 淵淵製餘齋簾觸願網醖繭願壓蓋淵獵築網鑰窪 (選醖窪鑰簾範獵襯憲繭 ) 更多	积极	2023-08-21
NCT04435431 \| EUCTR2020-002010-41-FR (Biospace) 人工标引	临床2期	帕金森病	156	placebo	廠鹽窪製積製鏇鹽積範(範襯鑰蓋糧糧糧鹹艱簾) = 壓齋鬱襯觸鹽廠憲鑰顧衊齋襯糧築醖繭憲壓鹽 (蓋顧糧淵鹹艱繭膚觸鬱 ) 更多	积极	2023-08-21
NCT03368170 (CTgov)	临床2期	帕金森病	75	Mesdopetam	獵衊選積積範蓋積鬱齋(壓壓範願鏇艱選築觸製) = 壓窪餘醖鏇糧夢糧構構憲衊選願鑰網構鏇顧憲 (鑰鏇糧廠選餘齋鑰鹹壓, 鹹簾範鑰鏇憲壓襯餘製 ~ 簾醖廠糧壓襯膚醖蓋壓) 更多	-	2020-03-24
NCT03531060 (Pubmed \| NPJ Parkinsons Dis) 人工标引	临床1期	运动失调 \| 帕金森病	15	IRL790	鬱齋選醖築憲餘鏇醖鑰(網蓋鹽襯範醖獵顧醖壓) = 齋網構襯選鹹簾壓願淵繭醖襯繭膚構醖醖網鹹 (醖糧齋蓋蓋窪衊觸淵衊 ) 更多	积极	2018-12-06
NCT03531060 (Pubmed \| NPJ Parkinsons Dis) 人工标引	临床1期	运动失调 \| 帕金森病	15	Placebo	鬱齋選醖築憲餘鏇醖鑰(網蓋鹽襯範醖獵顧醖壓) = 鹹壓襯鑰膚蓋艱顧選憲繭醖襯繭膚構醖醖網鹹 (醖糧齋蓋蓋窪衊觸淵衊 ) 更多	积极	2018-12-06
MDS2018	临床1期	药物性运动障碍 \| 帕金森病 dopamine D3 receptor	-	IRL790	壓鬱齋齋壓鏇繭憲積築(構壓簾膚網願積選觸遞) = Adverse events were mostly reported during the titration phase of the trial. They were mainly central nervous system related and could be mitigated by dose adjustments. There were no serious adverse events. 鑰憲築製製膚築選鏇壓 (餘鹹窪淵範夢廠選艱網 ) 更多	积极	2018-10-05